Furthermore, GLP-1-Fc-FGF21 D1 also offered more significant therapeutic effects in attenuating NASH progression regarding hepatic function, lipid profiles, and NAS scores than the single agonists. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatohepatitis.